Iovance Biotherapeutics Inc (NASDAQ:IOVA)’s traded shares stood at 17.43 million during the last session, with the company’s beta value hitting 0.55. At the close of trading, the stock’s price was $8.18, to imply a decrease of -4.77% or -$0.41 in intraday trading. The IOVA share’s 52-week high remains $18.33, putting it -124.08% down since that peak but still an impressive 47.07% since price per share fell to its 52-week low of $4.33. The company has a valuation of $2.49B, with an average of 9.68 million shares in intraday trading volume over the past 10 days and average of 5.91 million shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for Iovance Biotherapeutics Inc (IOVA), translating to a mean rating of 1.40. Of 8 analyst(s) looking at the stock, 0 analyst(s) give IOVA a Sell rating. 0 of those analysts rate the stock as Overweight while 2 advise Hold as 6 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -0.26.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Iovance Biotherapeutics Inc (NASDAQ:IOVA) trade information
After registering a -4.77% downside in the last session, Iovance Biotherapeutics Inc (IOVA) has traded red over the past five days. The 5-day price performance for the stock is -22.72%, and -19.57% over 30 days. With these gigs, the year-to-date price performance is 0.62%. Short interest in Iovance Biotherapeutics Inc (NASDAQ:IOVA) saw shorts transact 59.73 million shares and set a 13.08 days time to cover.
The extremes give us $6 and $40 for target low and target high price respectively. As such, IOVA has been trading -389.0% off suggested target high and 26.65% from its likely low.
Iovance Biotherapeutics Inc (IOVA) estimates and forecasts
Looking at statistics comparing Iovance Biotherapeutics Inc share performance against respective industry, we note that the company has outperformed competitors. Iovance Biotherapeutics Inc (IOVA) shares are -20.12% down over the last 6 months, with its year-to-date growth rate higher than industry average at 33.86% against 17.70%. Revenue is forecast to grow 41.88% this quarter before jumping 38.78% for the next one. The rating firms project that company’s revenue will grow 13,525.93% compared to the previous financial year.
Revenue forecast for the current quarter as set by 13 analysts is 71.57M. Meanwhile, for the current quarter, a total of 8 analyst(s) estimate revenue growth to 88.59M.Earnings reports from the last fiscal year show that sales brought in 482k and 715k respectively in the corresponding quarters. In this case, analysts estimate current quarter sales to rise 14,748.60% before jumping 12,289.93% in the following quarter.
IOVA Dividends
Iovance Biotherapeutics Inc has its next earnings report out on 2025-Feb-26. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
Iovance Biotherapeutics Inc (NASDAQ:IOVA)’s Major holders
Iovance Biotherapeutics Inc insiders hold 0.53% of total outstanding shares, with institutional holders owning 88.31% of the shares at 88.78% float percentage. In total, 88.31% institutions holds shares in the company, led by VANGUARD GROUP INC. As of 2024-06-30, the company held over 25.95 million shares (or 9.7478% of shares), all amounting to roughly $208.12 million.
The next major institution holding the largest number of shares is PERCEPTIVE ADVISORS LLC with 25.93 million shares, or about 9.7412% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $207.98 million.
